Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Oncolytics Biotech's share price for the quarter that ended in Dec. 2024 was C$1.33. Oncolytics Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 80.02 Mil. Therefore, Oncolytics Biotech's market cap for the quarter that ended in Dec. 2024 was C$106.43 Mil.
Oncolytics Biotech's quarterly market cap
declined
from Jun. 2024 (C$103.76 Mil) to Sep. 2024 (C$91.72 Mil) but then
increased
from Sep. 2024 (C$91.72 Mil) to Dec. 2024 (C$106.43 Mil).
Oncolytics Biotech's annual market cap
declined
from Dec. 2022 (C$136.15 Mil) to Dec. 2023 (C$133.22 Mil) and
declined
from Dec. 2023 (C$133.22 Mil) to Dec. 2024 (C$106.43 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Oncolytics Biotech's Enterprise Value for Today is C$57.00 Mil.
Oncolytics Biotech Market Cap Historical Data
The historical data trend for Oncolytics Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oncolytics Biotech's Market Cap
For the Biotechnology subindustry, Oncolytics Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolytics Biotech's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Oncolytics Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Oncolytics Biotech's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolytics Biotech (TSX:ONC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Oncolytics Biotech Market Cap Related Terms
Thank you for viewing the detailed overview of Oncolytics Biotech's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSX:ONC has been successfully added to your 